BioSpace News Archive

PROOF 302 Trial Enrolling Subjects with Invasive Urothelial Carcinoma with Susceptible FGFR3 Genetic Alterations Ohio State University-Led Trial to Study Infigratinib for Treatment of Patients with Advanced or Metastatic Solid Tumors with FGFR Genetic Alterations

resTORbio, Inc. reported financial results for the fourth quarter and full year ended December 31, 2019.

Idera Pharmaceuticals, Inc.reported on March 11, 2020 its financial and operational results for the fourth quarter and year ended December 31, 2019.

Data from study on Tumor Treating Fields in combination with anti-PD-1 therapy published in Cancer Immunology, Immunotherapy

Agenus provided a corporate update and reported financial results for the fourth quarter and full year of 2019.

Tetraphase Pharmaceuticals, Inc.today reported financial results for the fourth quarter and year ended December 31, 2019.

X4 Pharmaceuticals, Inc. today provided a corporate update and reported financial results for the fourth quarter and full year ended December 31, 2019

EXUMA Biotech Corp. (formerly F1 Oncology), a clinical-stage biotechnology company discovering and developing CAR-T therapies for solid and liquid tumors, today announced a $19M Series B round of financing that includes new investments by MSD Partners and F1 BioVentures, as well as conversion of notes held by individual investors.

Denovo Biopharma LLC, a pioneer in applying precision medicine to develop innovative therapies, today announced it has successfully discovered a novel genetic biomarker associated with DB104 response to treat depression using its proprietary bi

The U.S. Food and Drug Administration (FDA) has granted Fast Track designation for the investigation of Jardiance® (empagliflozin) to reduce the risk of kidney disease progression and cardiovascular death in adults with chronic kidney disease, Boehringer Ingelheim and Eli Lilly and Company (NYSE: LLY) announced.